Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.
Gray, W.T., Frey, K.M., Laskey, S.B., Mislak, A.C., Spasov, K.A., Lee, W.G., Bollini, M., Siliciano, R.F., Jorgensen, W.L., Anderson, K.S.(2015) ACS Med Chem Lett 6: 1075-1079
- PubMed: 26487915 
- DOI: https://doi.org/10.1021/acsmedchemlett.5b00254
- Primary Citation of Related Structures:  
5C42 - PubMed Abstract: 
Catechol diether compounds have nanomolar antiviral and enzymatic activity against HIV with reverse transcriptase (RT) variants containing K101P, a mutation that confers high-level resistance to FDA-approved non-nucleoside inhibitors efavirenz and rilpivirine. Kinetic data suggests that RT (K101P) variants are as catalytically fit as wild-type and thus can potentially increase in the viral population as more antiviral regimens include efavirenz or rilpivirine. Comparison of wild-type structures and a new crystal structure of RT (K101P) in complex with a leading compound confirms that the K101P mutation is not a liability for the catechol diethers while suggesting that key interactions are lost with efavirenz and rilpivirine.
Organizational Affiliation: 
Department of Pharmacology, Yale University School of Medicine , New Haven, Connecticut 06520-8066, United States.